IPP Bureau
Johnson & Johnson strikes deal With Trump admn to cut drug costs, expand manufacturing
By IPP Bureau - January 11, 2026
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
Alveus Therapeutics launches with $159.8m Series A to advance next-gen obesity drugs
By IPP Bureau - January 11, 2026
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
Nxera secures exclusive APAC rights to DMD drug Vamorolone in deal with Santhera
By IPP Bureau - January 11, 2026
Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
Halozyme and Takeda team up to transform Crohn’s and Colitis Therapy
By IPP Bureau - January 11, 2026
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
Pulmocide halts Phase 3 trial of Opelconazole in severe lung infection
By IPP Bureau - January 11, 2026
The decision follows an interim analysis conducted when roughly half of the patients had completed their Day 84 visit
Ollin Biosciences’ bispecific antibody outperforms Faricimab in head-to-head Phase 1b trial
By IPP Bureau - January 11, 2026
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
NRG Therapeutics doses first participants in landmark ALS & Parkinson’s trial
By IPP Bureau - January 11, 2026
The mPTP plays a key role in mitochondrial dysfunction, inflammation, and neuronal death in neurodegenerative diseases
InflaRx shifts focus to lead drug, cuts costs by 30% to extend cash runway
By IPP Bureau - January 11, 2026
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
Merck initiates phase 3 trial of calderasib with Keytruda QLEX for NSCLC
By IPP Bureau - January 11, 2026
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
Prokaryotics and Basilea team up to tackle deadly fungal infections
By IPP Bureau - January 11, 2026
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
PAI Pharma acquires Nivagen to boost US injectable drug production
By IPP Bureau - January 11, 2026
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
AstraZeneca names Rick R. Suarez as US President and Head of US BioPharmaceuticals Business Unit
By IPP Bureau - January 10, 2026
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
AstraZeneca appoints Laura Colon as new President of Spain
By IPP Bureau - January 10, 2026
After leading AstraZeneca's Oncology areas nationally and internationally, Laura Colón will assume the presidency of AstraZeneca in one of its priority global markets
Revvity and Lilly partner to accelerate AI drug discovery models
By IPP Bureau - January 10, 2026
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
Shilpa Medicare aims for US approval of chemo nausea drug
By IPP Bureau - January 09, 2026
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
